Business Description
Biotechnology Assets SA
ISIN : ES0184980003
Total Employee Number:
27Compare
Compare
Traded in other countries / regions
BST.Spain041.Germany IPO Date
2011-06-14Description
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | 0.51 | |||||
Debt-to-Equity | 0.58 | |||||
Debt-to-EBITDA | 7.22 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -1.09 | |||||
Beneish M-Score | -2.96 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -3.6 | |||||
3-Year EPS without NRI Growth Rate | 17.8 | |||||
3-Year FCF Growth Rate | 49.6 | |||||
3-Year Book Growth Rate | 9.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.98 | |||||
9-Day RSI | 59.34 | |||||
14-Day RSI | 55.08 | |||||
3-1 Month Momentum % | -9.05 | |||||
6-1 Month Momentum % | 9.33 | |||||
12-1 Month Momentum % | -41.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.4 | |||||
Quick Ratio | 1.4 | |||||
Cash Ratio | 0.18 | |||||
Days Sales Outstanding | 365.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.3 | |||||
Shareholder Yield % | -14.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 103.56 | |||||
Operating Margin % | -22.84 | |||||
Net Margin % | -62.02 | |||||
EBITDA Margin % | 17.96 | |||||
FCF Margin % | -11.52 | |||||
OCF Margin % | -0.42 | |||||
ROE % | -28.71 | |||||
ROA % | -13.76 | |||||
ROIC % | -5.59 | |||||
3-Year ROIIC % | -15.57 | |||||
ROC (Joel Greenblatt) % | -37.55 | |||||
ROCE % | -14.2 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.25 | |||||
PB Ratio | 2.35 | |||||
Price-to-Tangible-Book | 5.65 | |||||
Price-to-Operating-Cash-Flow | 226 | |||||
EV-to-EBIT | -13.93 | |||||
EV-to-EBITDA | 36.7 | |||||
EV-to-Forward-EBITDA | 2.63 | |||||
EV-to-Revenue | 6.58 | |||||
EV-to-Forward-Revenue | 0.65 | |||||
EV-to-FCF | -57.42 | |||||
Price-to-GF-Value | 0.78 | |||||
Price-to-Median-PS-Value | 0.71 | |||||
Earnings Yield (Greenblatt) % | -7.17 | |||||
FCF Yield % | -2.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biotechnology Assets SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3.091 | ||
| EPS (TTM) (€) | -0.027 | ||
| Beta | -0.0253 | ||
| 3-Year Sharpe Ratio | -0.23 | ||
| 3-Year Sortino Ratio | -0.34 | ||
| Volatility % | 57.67 | ||
| 14-Day RSI | 55.08 | ||
| 14-Day ATR (€) | 0.010596 | ||
| 20-Day SMA (€) | 0.21455 | ||
| 12-1 Month Momentum % | -41.71 | ||
| 52-Week Range (€) | 0.176 - 0.475 | ||
| Shares Outstanding (Mil) | 75.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biotechnology Assets SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biotechnology Assets SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-10-30 | In 79 days | ||
| General meeting for 2026 | 2026-06-29 12:00 | 0.23 (-2.59%) | ||
| Annual report for 2025 | 2026-04-30 | 0.28 (+4.49%) | ||
| Second quarter earnings results for 2025 | 2025-10-30 | 0.35 (+1.16%) | ||
| General meeting for 2025 | 2025-06-18 12:00 | 0.32 (+2.92%) | ||
| Annual report for 2024 | 2025-04-30 | 0.32 (+1.26%) | ||
| Second quarter earnings results for 2024 | 2024-10-25 | 0.29 (-0.17%) |
Show
Entries
Biotechnology Assets SA Frequently Asked Questions
What is Biotechnology Assets SA(XMAD:BST)'s stock price today?
The current price of XMAD:BST is €0.23. The 52 week high of XMAD:BST is €0.48 and 52 week low is €0.18.
When is next earnings date of Biotechnology Assets SA(XMAD:BST)?
The next earnings date of Biotechnology Assets SA(XMAD:BST) is 2026-10-30 Est..
Does Biotechnology Assets SA(XMAD:BST) pay dividends? If so, how much?
Biotechnology Assets SA(XMAD:BST) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Biotechnology Assets SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers